| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $109K | — | +1081.9% |
| SG&A Expense | $1.1M | — | +202.5% |
| Operating Income | -$1.2M | — | -223.7% |
| Net Income | -$971K | — | -195.5% |
| EPS (Basic) | -$0.03 | — | -200.0% |
| EPS (Diluted) | -$0.03 | — | -200.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $11.0M | +173.3% | — |
| Current Assets | $11.5M | +120.4% | — |
| Total Assets | $18.6M | +53.3% | — |
| Current Liabilities | $5.1M | -14.5% | — |
| Long-term Debt | $7.3M | — | — |
| Total Liabilities | $12.5M | +67.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.6M | — | -447.8% |
| Investing Cash Flow | -$12K | — | — |
| Financing Cash Flow | $7.8M | — | +680.1% |
| Stockholders' Equity | $6.1M | +30.5% | +647.2% |